These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 9591585)
21. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. Deshpande SV; DeNardo SJ; Kukis DL; Moi MK; McCall MJ; DeNardo GL; Meares CF J Nucl Med; 1990 Apr; 31(4):473-9. PubMed ID: 2324823 [TBL] [Abstract][Full Text] [Related]
22. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma. Lubic SP; Goodwin DA; Meares CF; Song C; Osen M; Hays M J Nucl Med; 2001 Apr; 42(4):670-8. PubMed ID: 11337558 [TBL] [Abstract][Full Text] [Related]
29. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re. van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186 [TBL] [Abstract][Full Text] [Related]
30. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078 [TBL] [Abstract][Full Text] [Related]
31. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse. Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230 [TBL] [Abstract][Full Text] [Related]
32. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230 [TBL] [Abstract][Full Text] [Related]
33. Targeting strategies for cancer radiotherapy. Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342 [TBL] [Abstract][Full Text] [Related]
34. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Ruegg CL; Anderson-Berg WT; Brechbiel MW; Mirzadeh S; Gansow OA; Strand M Cancer Res; 1990 Jul; 50(14):4221-6. PubMed ID: 2364380 [TBL] [Abstract][Full Text] [Related]
35. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Adams GP; Shaller CC; Dadachova E; Simmons HH; Horak EM; Tesfaye A; Klein-Szanto AJ; Marks JD; Brechbiel MW; Weiner LM Cancer Res; 2004 Sep; 64(17):6200-6. PubMed ID: 15342405 [TBL] [Abstract][Full Text] [Related]
36. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Riva P; Franceschi G; Frattarelli M; Lazzari S; Riva N; Giuliani G; Casi M; Sarti G; Guiducci G; Giorgetti G; Gentile R; Santimaria M; Jermann E; Maeke HR Clin Cancer Res; 1999 Oct; 5(10 Suppl):3275s-3280s. PubMed ID: 10541375 [TBL] [Abstract][Full Text] [Related]